Tranexamic acid is an antifibrinolytic agent and inhibits the activation of
plasminogen to plasmin.
Trial data (CRASH-2)1 showed that the administration of tranexamic acid to adult
trauma patients with, or at risk of, significant haemorrhage, within 8 hours of
injury significantly reduces all-cause mortality with no apparent increase in vascular
occlusive events.
- Early use of tranexamic acid should be considered for all patients with trauma and significant haemorrhage.
- Patients with isolated head injury should not routinely receive tranexamic acid as risk of thrombosis exists.
- Use within 3 hours of injury is recommended.
- Initial use of tranexamic acid should be avoided when time from injury is known or suspected to be greater than 3 hours.
- Tranexamic acid is given as 1 gram loading dose in 100ml 0.9% normal saline over 10 min in a separate line from blood or blood products.
- Infuse a second 1 gram dose of tranexamic acid in 0.9% normal saline over 8 hours.
- There is no evidence from randomised trials to support additional administration of tranexamic acid in trauma patients after the initial two doses. Further use should be discussed with an on-call haematology consultant.
→ Section 11.a
Tranexamic acid
The East of England Ambulance NHS Trust has developed a PGD in conjunction with the Trauma Network for paramedic administration of tranexamic acid in the first 3 hours after injury.
References
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial, The Lancet, Vol 376, issue 9734, 23-32; 3 July 2010